Ardelyx Posts $127.7M in Q3 Revenue, Topping Last Quarter's Record
ARDX is trading near its 52-week low of $2.955 (3.2% above the low).
Summary
Ardelyx reported third-quarter revenue of $127.7M, ahead of the $120.9M it booked in Q2 and the $118.1M in Q2 product revenue, with Q3 product sales of USD 125.455 Million. That extends the top-line growth trend that drove Q2's 24% year-over-year increase, though the prior quarter came with a $60M cut to full-year IBSRELA guidance that has kept the stock pinned near its 52-week low of $2.955. The quarter's bottom line came in at a loss of $737,000, or 0c per share. The revenue print alone doesn't resolve the guidance question — the market will want the updated IBSRELA outlook and any commentary on the commercial organization after Chief Commercial Officer Eric Foster's August departure. Cash stood at $281.8M at the end of Q2, so the revenue trajectory matters more for the growth story than for liquidity.
At the time of this announcement, ARDX was trading at $3.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $755M. The 52-week trading range was $2.96 to $8.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.